फंड का अवलोकन
ARK Genomic Revolution ETF (ARKG) is a specialized investment vehicle categorized within the Health sector, managed by the ARK ETF Trust family. The fund currently oversees Total Assets under management of $1.04 billion, a scale that indicates significant institutional interest and market recognition despite its niche focus on genomic technologies. While the specific number of individual holdings is not publicly disclosed in current data, the lack of this metric suggests a concentrated portfolio structure typical of active thematic funds rather than broad market diversification. Investors must account for an expense ratio of 0.8%, which represents a higher operational cost compared to standard passive index funds, potentially eroding net returns over extended investment horizons due to the active management fees incurred.
प्रदर्शन विश्लेषण
The current annualized yield for ARKG stands at 0.0%, indicating that the fund generates no distribution income for investors seeking passive cash flow or dividend reinvestment strategies within the health sector. For the current fiscal year to date, the fund has recorded a return of -8.6%, reflecting a negative performance trajectory relative to its inception and broader market benchmarks over this specific period. When examining longer-term consistency, the fund has delivered a 3-year average return of -3.1% and a 5-year average return of -20.9%, figures that suggest a pattern of underperformance and capital erosion over the medium-to-long term. Comparing the short-term decline of -8.6% against the substantial long-term drag of -20.9% over five years highlights the persistent challenges faced by genomic innovation stocks in generating positive alpha. Furthermore, the 0.8% expense ratio compounds annually, meaning that without significant outperformance, the cumulative cost of management fees will continue to diminish the gross appreciation of the underlying portfolio, making high-fee active strategies particularly sensitive to periods of market stagnation or decline.
Price & Risk Profile
The security has traded within a 52-week range defined by a high of $34.39 and a low of $20.21, illustrating a wide price band that signals substantial volatility inherent to thematic equity investments. Based on the 52-week high and low, the current trading price is situated closer to the lower end of this historical range, suggesting the asset has experienced a correction from its recent peak levels. The fund's beta is listed as N/A, which prevents a direct quantitative comparison of its volatility relative to the broader market index, though the wide price range implies sensitivity to specific sector headwinds. Consequently, the overall risk profile is characterized by high equity risk and significant price fluctuation, making the instrument suitable primarily for investors with a high tolerance for capital variability who are specifically targeting genomic advancements rather than seeking stability or income.